Dermal Fillers: Why Who Injects You Matters More Than What They Inject

Dermal fillers are sold on the result — a lifted cheek, a softer line, a balanced profile. What almost never features in the marketing is the fact that this is an injection into a face densely supplied with blood vessels, and that the difference between a routine appointment and a serious complication is largely decided before anyone picks up a syringe.

The most important variable in filler safety is not the product. It is who is holding it, and what they have in the room if something goes wrong.

What fillers actually are

Most modern dermal fillers are gels of hyaluronic acid, a substance the body already produces. They work by occupying space — restoring volume, supporting structure, softening a fold — and they break down gradually over months to a couple of years depending on the product and the site.

They are frequently confused with neuromodulators, which are an entirely different class. Neuromodulators relax specific muscles to soften movement lines; fillers add volume. One reduces motion, the other occupies space — and a consultation that treats them as interchangeable is not assessing the face properly. Our overview of non-surgical options for facial ageing sets out where each fits.

The complication that defines this field

The serious risk in filler treatment is vascular occlusion: filler entering or compressing a blood vessel and cutting off supply to the tissue it feeds.

Downstream, that means skin that does not receive blood. Early signs are recognisable to someone trained to look — disproportionate pain, sudden blanching, a dusky or mottled pattern developing over the treated area. Untreated, it can progress to tissue death and scarring. In the worst cases, filler travelling backwards along an artery toward the eye can cause visual loss.

This is rare. It is also not theoretical. One literature review identified 233 reported cases of filler-induced visual loss, with severe visual impairment in at least one eye in 172 of them, and case numbers have been rising as the treatment has become more widely available.

Set against that, it helps to know what is simply expected. Bruising, swelling, tenderness, mild asymmetry while swelling settles, and small palpable lumps that soften over a week or two are all ordinary and self-limiting. The distinguishing feature is direction and proportion: normal recovery improves day by day and hurts less than you expected, whereas a vascular problem announces itself with pain that is worse than the procedure warranted, colour change rather than simple bruising, and a picture that deteriorates instead of settling. Anything getting worse after the first day is a reason to call, not to wait.

How rare is rare?

Vision loss after facial injection is generally estimated at around 0.001% of procedures — vanishingly uncommon against the volume of treatments performed. Localised vascular occlusion without eye involvement is more common than that, though still unusual.

Two caveats matter. Published reviews consistently note under-reporting, so figures represent a floor rather than a ceiling. And a risk being small across a population is not the same as a risk being managed in the room you are sitting in. The population number is set by anatomy; your individual odds are heavily influenced by technique, product choice and what happens in the first hour if something goes wrong.

Why reversibility is the biggest safety decision

Hyaluronic acid fillers can be dissolved with an enzyme called hyaluronidase. That single property is the reason they dominate responsible practice.

If a vessel is compromised, hyaluronidase can break down the obstructing gel and restore flow. Reviews of its use in managing aesthetic complications describe it as the cornerstone of emergency management. It is also why an unsatisfactory cosmetic result is correctable rather than something to endure.

Materials that are not hyaluronic acid — including transferred fat and various long-lasting synthetics — do not have this escape route. Reviews of vascular events note that while hyaluronic acid accounts for most reported cases (largely because it is most used), non-reversible materials are associated with more severe and less salvageable outcomes. For a first-time patient, reversibility is worth more than longevity.

The emergency that runs on a clock

This is the part that separates a clinic from a salon offering the same service at a better price.

Managing vascular occlusion is time-critical. Published guidance describes prompt, repeated, high-dose hyaluronidase as capable of reversing ischaemia in a large majority of cases when started within the first several hours. Where the eye is involved, the window discussed in the literature is measured in tens of minutes, not hours.

A clinic without hyaluronidase in the building cannot act inside that window. Neither can one that does not recognise what it is looking at. This is the entire argument for treating injectables as a medical procedure rather than a beauty service — not because complications are common, but because the response to them cannot be improvised.

What to ask before anyone injects you

Who is injecting, and what is their medical qualification? Not their certificate from a product training day — their clinical qualification, and how long they have been treating the specific area you are asking about.

What product are you using, and is it reversible? The answer should be specific, and for a first treatment it should be hyaluronic acid.

Do you keep hyaluronidase on site? The only acceptable answer is yes, immediately available.

What is your protocol if a vascular occlusion occurs? A confident, rehearsed answer tells you more than any portfolio.

What happens if I do not like it? Reversibility should be discussed before treatment, not after.

A practitioner who welcomes these questions is the one you want. A practitioner who finds them insulting has answered them.

When fillers are the wrong answer

Volume loss, skin laxity and skin quality are three different problems that can look similar in a mirror, and only the first is a filler problem.

Adding volume to skin whose main issue is laxity tends to produce heaviness rather than lift, which is why tightening approaches are assessed alongside rather than instead of injectables — our guide to non-surgical skin tightening covers that side. Where the complaint is really texture, dullness or pigmentation, no amount of volume addresses it.

There is also the cumulative problem. Faces treated repeatedly without reassessment can drift away from proportion rather than toward it, because each individual appointment seemed reasonable in isolation. A practitioner willing to say “not this time” is protecting the result. Understanding what actually changes as skin ages helps separate the concerns that injectables suit from the ones they do not.

How a clinical assessment approaches injectables

A responsible assessment starts with the face at rest and in motion, not with a product list. It establishes which of volume, laxity, muscle activity and skin quality is actually driving the complaint, because the treatment that follows differs entirely depending on the answer.

It includes medical history — anticoagulants, autoimmune conditions, previous injectable treatments and what was used, active infection or inflammation at the site — and a frank conversation about what a personalised, clinically supervised plan can achieve on your anatomy. Consent should cover vascular occlusion explicitly, with the reversal plan described rather than mentioned. Comfort measures are worth discussing too, and our note on modern comfort techniques covers what is available.

The precision that matters in injectables is anatomical, not aesthetic. An evidence-based plan is built by someone who knows exactly what lies under the point of the needle — and who has planned for the day something does not go as expected.